PartnershipJul 28, 2026, 07:51 AM
Firefly Neuroscience Partners with Next Health for Cognitive Platform
AI Summary
Firefly Neuroscience, an AI company advancing precision neuroscience, announced a strategic partnership with Next Health, a leader in health optimization. The collaboration will launch a novel precision cognitive health platform, integrating Firefly's AI-powered, FDA-cleared EEG/ERP brain biomarker technology with Next Health's personalized cognitive peptide protocols. This initiative follows an FDA Advisory Committee recommendation to ease compounding restrictions for peptides like Epitalon and Semax, which have potential neuroprotective properties. The partnership aims to provide objective measures of brain function to personalize, monitor, and optimize emerging cognitive therapies.
Key Highlights
- Firefly Neuroscience partnered with Next Health to launch a novel precision cognitive health platform.
- The platform integrates Firefly's AI-powered, FDA-cleared EEG/ERP brain biomarker technology.
- Next Health will provide personalized cognitive peptide protocols, including Epitalon and Semax.
- FDA Advisory Committee recommended easing compounding restrictions for six peptides, including Epitalon and Semax.
- The initiative aims to provide physicians with objective measures of brain function for personalized therapies.
- The collaboration seeks to replace subjective cognitive assessments with data-driven clinical decision-making.
- The initiative will leverage Next Health's rapidly expanding network of longevity clinics.
Price Impact
More from AIFF